A Phase 1a/1b, Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, and Anti-tumour Activity of AK127 in Combination With AK104 in Subjects With Advanced or Metastatic Solid Tumours
Latest Information Update: 27 Mar 2024
At a glance
- Drugs AK 127 (Primary) ; Cadonilimab (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Akeso Biopharma
- 05 Jan 2023 Planned End Date changed from 1 May 2023 to 7 Apr 2025.
- 05 Jan 2023 Planned primary completion date changed from 1 Mar 2023 to 10 Jan 2025.
- 21 Oct 2021 Status changed from not yet recruiting to recruiting according to Akeso Biopharma media release